Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy-Reference-Cited by-同舟云学术

Case Report: Emergent Resistance in a Treatment-Naive Person With Human Immunodeficiency Virus Under Bictegravir-Based Therapy

Published:2021-06-01 Issue:6 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Chamberlain Nicholas¹,Mena Leandro²,Brock James Benjamin¹

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA

2. Department of Population Health Science, University of Mississippi Medical Center, Jackson, Mississippi, USA

Abstract

Abstract Few instances of treatment-emergent resistance to bictegravir have been reported in the literature. We describe a case of treatment-emergent resistance to bictegravir in a person recently diagnosed with human immunodeficiency virus who developed M184V and R263K mutations while on therapy.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab297/38490241/ofab297.pdf

Reference11 articles.

1. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors;Oliveira;AIDS,2014

2. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I;Andreatta;J Antimicrob Chemother,2019

3. Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient;Lozano;Antiviral Res,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-04-23

2. Treatment‐emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series;HIV Medicine;2023-06-14

3. Multiple drugs;Reactions Weekly;2023-04-22

4. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real‐world setting in Belgium;HIV Medicine;2023-04-10

5. HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report;Journal of Global Antimicrobial Resistance;2022-12